Research Topics
Genomes and GenesSpecies | Marla Cindy DubinskySummaryAffiliation: Cedars-Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Serologic and laboratory markers in prediction of the disease course in inflammatory bowel diseaseMarla Cindy Dubinsky
Pediatric IBD Center, Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
World J Gastroenterol 16:2604-8. 2010..The knowledge of an individual's prognosis can help physicians and patients make important management decisions and aid communication on risk and benefits of disease and treatment...- Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel diseaseMarla C Dubinsky
Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Inflamm Bowel Dis 16:1357-66. 2010.... 
Management of the pregnant IBD patientMarla Dubinsky
Department of Pediatrics, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Inflamm Bowel Dis 14:1736-50. 2008..We would like to emphasize that the information presented here must be individualized to the specific situation of each patient, their acceptance of risk, and their degree of disease severity...
New patients: should children be treated differently?M C Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Colorectal Dis 8:15-9. 2006..A recent case report, involving a 15-year old boy presenting with abdominal pain and bloody diarrhoea, illustrates the difficulty in correctly diagnosing IBD in children and the need for optimizing therapy to achieve treatment success...- Monitoring of AZA/6-MP treatment in children with IBD is necessaryMarla C Dubinsky
Pediatric Gastroenterology, Cedars-Sinai Hospital, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 9:386-8; discussion 392-3. 2003 - Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprineMarla C Dubinsky
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Am J Gastroenterol 98:1058-63. 2003..Despite these favorable results, candidates for 6-TG should be selected with caution, and its use should be reserved for IBD patients well informed about potential toxicities... - 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel diseaseMarla C Dubinsky
Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
Gastroenterology 122:904-15. 2002..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT... - Genome-wide association identifies multiple ulcerative colitis susceptibility lociDermot P B McGovern
Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Nat Genet 42:332-7. 2010..These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis... - Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel diseaseStephen A Geller
Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Surg Pathol 28:1204-11. 2004..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease... - Immunogenetic phenotypes in inflammatory bowel diseaseMarla C Dubinsky
Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
World J Gastroenterol 12:3645-50. 2006.... - A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurineMarla C Dubinsky
Department of Pediatrics, Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Am J Gastroenterol 100:2239-47. 2005.... - IL-23 receptor (IL-23R) gene protects against pediatric Crohn's diseaseMarla C Dubinsky
Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
Inflamm Bowel Dis 13:511-5. 2007..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients... - Optimizing immunomodulator therapy for inflammatory bowel diseaseMarla C Dubinsky
Pediatric IBD Center, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 1165W, Los Angeles, CA 90048, USA
Curr Gastroenterol Rep 5:506-11. 2003.... - Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safetyMarla C Dubinsky
Pediatric IBD Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Clin Gastroenterol Hepatol 2:731-43. 2004..By gaining an understanding of the pharmacology and metabolism of thiopurine therapy and putting it into the clinical context, clinicians will be able to optimize thiopurine therapy in IBD... - Increased immune reactivity predicts aggressive complicating Crohn's disease in childrenMarla C Dubinsky
Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 6:1105-11. 2008..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression... - Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progressionMarla C Dubinsky
Department of Pediatrics, Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
Am J Gastroenterol 101:360-7. 2006.... - A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
Inflamm Bowel Dis 10:333-8. 2004..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab... - Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel diseaseWilliam S Mow
Inflammatory Bowel Disease Center, Los Angeles, California, USA
Clin Gastroenterol Hepatol 2:31-40. 2004.... - Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?Marla C Dubinsky
Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
Rev Gastroenterol Disord 7:S3-7. 2007..Determining the factors that can predict the progression from uncomplicated to complicated disease states may stratify patients into at-risk populations and have an impact on their ultimate therapeutic management... - 6-thioguanine can cause serious liver injury in inflammatory bowel disease patientsMarla C Dubinsky
Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
Gastroenterology 125:298-303. 2003..The aim of this study was to describe the association between 6-TG and NRH in IBD... - Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximabKonstantinos A Papadakis
Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W. Third Street, Suite 430E, Los Angeles, CA 90048, USA
Am J Gastroenterol 100:75-9. 2005..CONCLUSIONS: Our preliminary data suggest that adalimumab may be a safe and effective therapy for patients with CD who have experienced an attenuated response to infliximab... - Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapySunita Shastri
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Arch Pathol Lab Med 128:49-53. 2004..Reticulin-stained histologic sections are necessary to recognize this change. Further studies are needed to determine the frequency and significance of this change... - Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati
Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Curr Gastroenterol Rep 11:238-47. 2009..This article examines the currently available published trials studying probiotics for the treatment of IBD, with particular emphasis on their role in pediatric IBD patients... - Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategiesMarla C Dubinsky
Department of Pediatrics, Cedars Sinai-Medical Center, University of California Los Angeles School of Medicine, USA
Am J Gastroenterol 97:2333-42. 2002..The economic benefits seem to be achieved by avoiding invasive evaluations in patients without IBD. Confirmation of these findings in a prospective comparative trial seems to be warranted... - Severe colitis in childrenSubra Kugathasan
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
J Pediatr Gastroenterol Nutr 41:375-85. 2005 - Case report: evidence for transplacental transfer of maternally administered infliximab to the newbornEric A Vasiliauskas
Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Clin Gastroenterol Hepatol 4:1255-8. 2006..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab... - Antibodies to I2 predict clinical response to fecal diversion in Crohn's diseaseJacob Spivak
Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Inflamm Bowel Dis 12:1122-30. 2006..CONCLUSION: Expression of I2 antibodies against a bacterial antigen of Pseudomonas fluorescens was highly associated with clinical response to fecal diversion in CD patients... - Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of AmericaAthos Bousvaros
J Pediatr Gastroenterol Nutr 44:653-74. 2007..quot; The authors hope that progress being made in genetic, serological, and imaging studies leads to more reliable phenotyping... - Disease perceptions among people with Crohn's diseaseSunanda V Kane
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Inflamm Bowel Dis 14:1097-101. 2008..We sought to characterize CD patient perceptions of both overall disease course and current symptomatology based on an objective symptom scale and to explore the relationship between perceptions and current symptoms... - Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBDShane M Devlin
Inflammatory Bowel Disease Center, The University of Calgary, Calgary, Alberta, Canada
Inflamm Bowel Dis 14:125-8; discussion 132-3. 2008 - Challenges in pediatric inflammatory bowel diseaseAthos Bousvaros
Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
Inflamm Bowel Dis 12:885-913. 2006..At the conclusion of the meeting, investigators discussed the formation of a multicenter collaborative network to advance clinical and basic research in the field...